The haptoglobin 2-2 genotype is associated with carotid atherosclerosis in 64-year old women with established diabetes

Clinica Chimica Acta

Volumn 411, Issue 7-8, 2010, Pages 500-504

  Ryndel, Mikael ^a   Behre, Carl Johan ^a,b   Brohall, Gerhard ^a,b   Prahl, Ulrica ^a   Schmidt, Caroline ^a   Bergström, Göran ^a,b   Fagerberg, Björn ^a   Olson, Fredrik J ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Arteriosclerosis; Cardiovascular risk factors; Carotid intima media thickness; Diabetes mellitus; Haptoglobin; Polymorphism

Indexed keywords

HAPTOGLOBIN; HAPTOGLOBIN 1 1; HAPTOGLOBIN 2 1; HAPTOGLOBIN 2 2; UNCLASSIFIED DRUG;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; SCREENING;

CAROTID ARTERY DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HAPTOGLOBINS; HUMANS; MIDDLE AGED;

EID: 77649179303     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.12.025     Document Type: Article

References (31)

1. Asleh R., Levy A.P. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005, 1:19-28.
2. Levy A.P., Purushothaman K.R., Levy N.S., et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 2007, 101:106-110.
3. Langlois M., Delanghe J., Philippe J., et al. Distribution of lymphocyte subsets in bone marrow and peripheral blood is associated with haptoglobin type. Binding of haptoglobin to the B-cell lectin CD22. Eur J Clin Chem Clin Biochem 1997, 35:199-205.
4. Cid M.C., Grant D.S., Hoffman G.S., Auerbach R., Fauci A.S., Kleinman H.K. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993, 91:977-985.
5. Langlois M.R., Delanghe J.R. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996, 42:1589-1600.
6. Chapelle J.P., Albert A., Smeets J.P., Heusghem C., Kulbertus H.E. Effect of the haptoglobin phenotype on the size of a myocardial infarct. N Engl J Med 1982, 307:457-463.
7. Delanghe J., Langlois M., Duprez D., De Buyzere M., Clement D. Haptoglobin polymorphism and peripheral arterial occlusive disease. Atherosclerosis 1999, 145:287-292.
8. Levy A.P., Hochberg I., Jablonski K., et al. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol 2002, 40:1984-1990.
9. Delanghe J., Cambier B., Langlois M., et al. Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery. Atherosclerosis 1997, 132:215-219.
10. Suleiman M., Aronson D., Asleh R., et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005, 54:2802-2806.
11. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
12. Costacou T., Ferrell R.E., Orchard T.J. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008, 57:1702-1706.
13. Dayan L., Levy A.P., Blum S., et al. Haptoglobin genotype and endothelial function in diabetes mellitus: a pilot study. Eur J Appl Physiol 2009, 106:639-644.
14. Asaf R., Blum S., Roguin A., et al. Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice. Cardiovasc Diabetol 2009, 8:29.
15. Burbea Z., Nakhoul F., Zoabi R., et al. Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients. Ann Clin Biochem 2004, 41:469-473.
16. De Bacquer D., De Backer G., Langlois M., Delanghe J., Kesteloot H., Kornitzer M. Haptoglobin polymorphism as a risk factor for coronary heart disease mortality. Atherosclerosis 2001, 157:161-166.
17. Levy A.P., Larson M.G., Corey D., Lotan R., Vita J.A., Benjamin E.J. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham offspring cohort. Atherosclerosis 2004, 172:361-365.
18. Asleh R., Marsh S., Shilkrut M., et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003, 92:1193-1200.
19. Wejman J.C., Hovsepian D., Wall J.S., Hainfeld J.F., Greer J. Structure and assembly of haptoglobin polymers by electron microscopy. J Mol Biol 1984, 174:343-368.
20. Brohall G., Behre C.J., Hulthe J., Wikstrand J., Fagerberg B. Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 2006, 29:363-367.
21. W.H.O Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20:1183-1197.
22. Nakhoul F.M., Zoabi R., Kanter Y., et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001, 44:602-604.
23. Wendelhag I., Liang Q., Gustavsson T., Wikstrand J. A new automated computerized analyzing system simplifies readings and reduces the variability in ultrasound measurement of intima-media thickness. Stroke 1997, 28:2195-2200.
24. Schmidt C., Wendelhag I. How can the variability in ultrasound measurement of intima-media thickness be reduced? Studies of interobserver variability in carotid and femoral arteries. Clin Physiol 1999, 19:45-55.
25. Touboul P.J., Hennerici M.G., Meairs S., et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007, 23:75-80.
26. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
27. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001, 285:2486-2497.
28. Koch W., Latz W., Eichinger M., et al. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002, 48:1377-1382.
29. Zarins C.K., Giddens D.P., Bharadvaj B.K., Sottiurai V.S., Mabon R.F., Glagov S. Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress. Circ Res 1983, 53:502-514.
30. Hulthe J., Wikstrand J., Emanuelsson H., Wiklund O., de Feyter P.J., Wendelhag I. Atherosclerotic changes in the carotid artery bulb as measured by B-mode ultrasound are associated with the extent of coronary atherosclerosis. Stroke 1997, 28:1189-1194.
31. Purushothaman K.R., Meerarani P., Moreno P.R. Inflammation and neovascularization in diabetic atherosclerosis. Indian J Exp Biol 2007, 45:93-102.